5-fluorouracil + dalteparin

This investigational combination therapy consists of the antimetabolite **5-fluorouracil (5-FU)** and the low molecular weight heparin (LMWH) **dalteparin**. Developed and studied by the **Universitätsklinikum Köln**, the combination was evaluated in the Phase 3 PRIVENT trial for the prevention of proliferative vitreoretinopathy (PVR) in high-risk patients undergoing surgery for rhegmatogenous retinal detachment. 5-FU acts as an antiproliferative agent by inhibiting thymidylate synthase, thereby preventing the multiplication of fibroblasts and retinal pigment epithelial (RPE) cells that contribute to scar tissue formation. Dalteparin, an anticoagulant, is intended to inhibit fibrin formation and cellular migration. Despite the mechanistic rationale, the PRIVENT trial results published in 2022 indicated that the adjuvant treatment did not significantly reduce the incidence of PVR compared to placebo.

Other names

5-fluorouracil and low molecular weight heparin5-FU and LMWH5-FU + dalteparin5-FU + LMWH